Studies

The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers.

Our Active Study Portfolio

Recent News +++

Metacure Trial: Can We Cure More Oligometastatic Prostate Cancer?

Press Releases by Cleveland Clinic January 14, 2020

Study combines hormonal therapy with prostatectomy and radiation therapy of bone lesions

Learn More

Phase I DSTP3086S Trial Results Published

Media Relations by PCCTC November 11, 2019

PCCTC study demonstrates safety and antitumor activity of humanized immunoglobulin G1 anti...

Learn More

PCCTC Investigators Drs. Rathkopf and McBride Receive Prestigious SU2C Grant

Press Releases by PCCTC October 17, 2019

Award will fund novel trial using immunotherapy combined with radiation and hormone therap...

Learn More

PCCTC Germline Genetics Working Group Publishes Results

Press Releases by PCCTC July 29, 2019

Study published in Clinical Genitourinary Cancer argues multidisciplinary efforts are key ...

Learn More

PCCTC Working Group Publishes Genetic Testing Manuscript

Press Releases by PCCTC April 26, 2019

Investigators from the Prostate Cancer Clinical Trials Consortium (PCCTC) formed the Germl...

Learn More

Phase III DORA Study Now Enrolling Patients with mCRPC

Press Releases by PCCTC April 19, 2019

The phase III DORA study (ClinicalTrials.gov Identifier: NCT03574571) led by PCCTC investi...

Learn More
View More News +

Follow Us

RT @DoraTrial: @DoraTrial, an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in sub…
RT @IRONMANregistry: 🇪🇸 ¡Bienvenido @chpcastellon (PI: @Dav_Lorente), the latest site to open our International Registry to Improve Outcome…
Olaparib (Lynparza), a drug developed in early phase @ThePCCTC trials, granted priority FDA review for certain type… https://t.co/VPEroRQott

Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.